Next Article in Journal
Quantitative Analysis of Hepatitis C NS5A Viral Protein Dynamics on the ER Surface
Previous Article in Journal
High-Mannose But Not Complex-Type Glycosylation of Tetherin Is Required for Restriction of HIV-1 Release
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessArticle
Viruses 2018, 10(1), 27; https://doi.org/10.3390/v10010027

Development of a Surrogate Neutralization Assay for Norovirus Vaccine Evaluation at the Cellular Level

1
Unit of Vaccinology and Antiviral Strategies, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China
2
University of Chinese Academy of Sciences, Beijing 100049, China
*
Authors to whom correspondence should be addressed.
Received: 8 December 2017 / Revised: 27 December 2017 / Accepted: 4 January 2018 / Published: 5 January 2018
(This article belongs to the Section Antivirals & Vaccines)
View Full-Text   |   Download PDF [3010 KB, uploaded 5 January 2018]   |  

Abstract

Noroviruses (NoVs) are the main pathogens responsible for sporadic and epidemic nonbacterial gastroenteritis, causing an estimated 219,000 deaths annually worldwide. There is no commercially available vaccine for NoVs, due partly to the difficulty in establishing NoV cell culture models. The histo-blood group antigen (HBGA) blocking assay is used extensively to assess the protective potential of candidate vaccine-elicited antibodies, but there is still no widely used cellular evaluation model. In this study, we have established a cell line-based NoV vaccine evaluation model through the construction of human α1,2-fucosyltransferase 2-overexpressing 293T (293T-FUT2) cell lines. The 293T-FUT2 cells stably expressed H type 2 and Lewis y antigens. Virus-like particles (VLPs) of the NoV prototype strain genogroup I.1 (GI.1) and the predominant strains GII.4 and GII.17 could attach to the cell line efficiently in a dose-dependent manner. Importantly, antisera against these NoV VLPs could inhibit the attachment of the VLPs, where the inhibitory effects measured by the attachment inhibition assay correlated significantly with the antibody levels determined by the HBGA blocking assay. Collectively, our attachment inhibition assay could serve as a surrogate neutralization assay for the evaluation of NoV vaccines at the cellular level. View Full-Text
Keywords: norovirus; histo-blood group antigen; α1,2-fucosyltransferase 2; vaccine evaluation model; cellular level norovirus; histo-blood group antigen; α1,2-fucosyltransferase 2; vaccine evaluation model; cellular level
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Wang, X.; Wang, S.; Zhang, C.; Zhou, Y.; Xiong, P.; Liu, Q.; Huang, Z. Development of a Surrogate Neutralization Assay for Norovirus Vaccine Evaluation at the Cellular Level. Viruses 2018, 10, 27.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top